Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 30% UP IN THE NEXT 72 HOURS -- Ignore unavailable to you. Want to Upgrade?

To: JRR4 who wrote (741)	3/31/1998 4:54:00 PM
From: Instock	Respond to of 1121

ALFACELL Awarded U.S. Patent for ONCONASE Variants Intellectual Property Portfolio Broadened BLOOMFIELD, N.J.--(BUSINESS WIRE)--March 31, 1998-- ALFACELL Corporation (NASDAQ: ACEL - news) announced today that it has been awarded United States Patent No. 5,728,805 which covers a family of variants of ONCONASE(R), the Company's flagship product. A patent covering the amino acid sequence of ONCONASE was issued in 1996 providing patent protection until the year 2013. The Company also owns other U.S. and foreign patents which cover ONCONASE, process technology for making ONCONASE and combinations of ONCONASE with certain other pharmaceuticals. ''The importance of this patent is that it broadens the patent protection of ALFACELL's technology platform by encompassing not only our flagship product, ONCONASE, but also other ribonucleases closely related to ONCONASE,'' stated Kuslima Shogen, CEO and Chairman of the Board of ALFACELL. ALFACELL Corporation is a leader in the development of ribonucleases (RNases) for therapeutic applications. ONCONASE, an antitumor agent, is currently being investigated in Phase III clinical trials in patients with advanced pancreatic adenocarcinoma and malignant mesothelioma. ALFACELL is located in Bloomfield, New Jersey. The Company's common stock is traded on NASDAQ under the symbol ''ACEL''. Instock